EVOQUE Tricuspid Valve Replacement System
Severe Tricuspid Regurgitation
PivotalEnrolling (TRISCEND II Trial)
Key Facts
Indication
Severe Tricuspid Regurgitation
Phase
Pivotal
Status
Enrolling (TRISCEND II Trial)
Company
About Edwards Lifesciences
Edwards Lifesciences is a patient-centric, global medical technology leader exclusively focused on structural heart disease solutions following its strategic 2024 divestiture of its Critical Care business. The company's mission is to deliver life-changing innovations, anchored by its dominant SAPIEN transcatheter aortic valve replacement (TAVR) platform, which has defined the standard of care. Its strategy involves reinvesting capital from the divestiture into R&D and clinical trials to expand indications, penetrate new geographies, and solidify its leadership in high-growth transcatheter mitral, tricuspid, and heart failure markets.
View full company profileTherapeutic Areas
Other Severe Tricuspid Regurgitation Drugs
| Drug | Company | Phase |
|---|---|---|
| DUO System | CroiValve | Pre-clinical |
| Versa Transcatheter Tricuspid Valve Repair System | Versa Vascular | Pre-clinical |